ClinicalTrials.gg

Program

deupsilocin

Its studies are mostly in Depressive Disorder, Major, led by Cybin IRL.

Furthest: phase 3, since Aug 20, 20243 company-led studies, 2 open or runningNext primary completion: Jun 7, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cybin IRL32 open or runningphase 3since Aug 20, 2024Aug 20, 2024Jun 7, 2027phase 3 · NCT06793397

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2024First study: phase 3 study in Depressive Disorder, MajorFirst studyNCT06564818 · 223 enrolled · United States
  2. Sep 16, 2024Phase 3 study in Depressive Disorder, MajorNCT06605105 · 468 planned · United States, Australia, Greece and more
  3. Jan 21, 2025Phase 3 study in Depressive Disorder, MajorNCT06793397 · 330 planned · United States, Australia, Czechia and more

Ahead

  1. Jun 7, 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06793397
  2. Jun 6, 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT06605105

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06793397Depressive Disorder, Major · United States, Australia, Czechia and more3RecruitingJun 7, 2027330
NCT06605105Depressive Disorder, Major · United States, Australia, Greece and more3By invitationJun 6, 2028468
NCT06564818Depressive Disorder, Major · United States3CompletedSep 4, 2026223

How it is read

Names in the registry

  • “CYB003”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.